Hormone and antihormone withdrawal: implications for the management of androgen-independent prostate cancer - PubMed (original) (raw)
Review
. 1996 Jan;47(1A Suppl):61-9.
doi: 10.1016/s0090-4295(96)80011-2.
Affiliations
- PMID: 8560680
- DOI: 10.1016/s0090-4295(96)80011-2
Free article
Review
Hormone and antihormone withdrawal: implications for the management of androgen-independent prostate cancer
H I Scher et al. Urology. 1996 Jan.
Free article
Abstract
Objectives: To analyze reported clinical outcomes for patients in whom an agent that acts via a steroid hormone receptor was "withdrawn."
Methods: Published reports where agent(s) known to act via steroid hormone receptors were discontinued in patients with relapsing prostatic cancer were retrieved from MEDLINE listings. The trials included patients who progressed on steroidal and nonsteroidal antiandrogens, progestational agents, and estrogens. Included were the specifics of all treatments administered prior to discontinuation of the drugs, concomitant therapies, and factors that might predict a favorable response to "withdrawal."
Results: Withdrawal responses were observed following the discontinuation of the antiandrogens flutamide and bicalutamide, flutamide plus aminoglutethimide, estrogens, and progestational agents. In most responding cases, responses were seen in patients with long exposure to the drug. No specific factors were predictive for response.
Conclusions: Withdrawal responses to agents that act via steroid hormone receptors represent a generalized phenomenon that can result in palliation for patients with hormonally relapsed prostate cancer. A trial of "withdrawal therapy" is warranted in patients with relapsing disease prior to the initiation of more toxic therapies. Failure to control for this phenomenon in clinical trials may lead to false attribution of response to a study agent. The data provide support for the concept that androgen independence does not necessarily mean that a tumor is resistant to further hormonal manipulations.
Similar articles
- The antiandrogen withdrawal syndrome in relapsed prostate cancer.
Scher HI, Kolvenbag GJ. Scher HI, et al. Eur Urol. 1997;31 Suppl 2:3-7; discussion 24-7. doi: 10.1159/000474540. Eur Urol. 1997. PMID: 9074903 - Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade.
Suzuki H, Okihara K, Miyake H, Fujisawa M, Miyoshi S, Matsumoto T, Fujii M, Takihana Y, Usui T, Matsuda T, Ozono S, Kumon H, Ichikawa T, Miki T; Nonsteroidal Antiandrogen Sequential Alternation for Prostate Cancer Study Group. Suzuki H, et al. J Urol. 2008 Sep;180(3):921-7. doi: 10.1016/j.juro.2008.05.045. Epub 2008 Jul 17. J Urol. 2008. PMID: 18635218 - Phase II study of suramin plus aminoglutethimide in two cohorts of patients with androgen-independent prostate cancer: simultaneous antiandrogen withdrawal and prior antiandrogen withdrawal.
Dawson N, Figg WD, Brawley OW, Bergan R, Cooper MR, Senderowicz A, Headlee D, Steinberg SM, Sutherland M, Patronas N, Sausville E, Linehan WM, Reed E, Sartor O. Dawson N, et al. Clin Cancer Res. 1998 Jan;4(1):37-44. Clin Cancer Res. 1998. PMID: 9516950 Clinical Trial. - Hormone-refractory (D3) prostate cancer: refining the concept.
Scher HI, Steineck G, Kelly WK. Scher HI, et al. Urology. 1995 Aug;46(2):142-8. doi: 10.1016/s0090-4295(99)80182-4. Urology. 1995. PMID: 7624983 Review. - The antiandrogen withdrawal syndrome.
Wirth MP, Froschermaier SE. Wirth MP, et al. Urol Res. 1997;25 Suppl 2:S67-71. doi: 10.1007/BF00941991. Urol Res. 1997. PMID: 9144890 Review.
Cited by
- Updates on Overcoming Bicalutamide Resistance: A Glimpse into Resistance to a Novel Antiandrogen.
Izady M, Khatami F, Ahadi Z, Roudgari H, Aghamir SMK. Izady M, et al. ACS Pharmacol Transl Sci. 2024 Mar 7;7(4):905-914. doi: 10.1021/acsptsci.3c00299. eCollection 2024 Apr 12. ACS Pharmacol Transl Sci. 2024. PMID: 38633597 Review. - Cellular androgen content influences enzalutamide agonism of F877L mutant androgen receptor.
Coleman DJ, Van Hook K, King CJ, Schwartzman J, Lisac R, Urrutia J, Sehrawat A, Woodward J, Wang NJ, Gulati R, Thomas GV, Beer TM, Gleave M, Korkola JE, Gao L, Heiser LM, Alumkal JJ. Coleman DJ, et al. Oncotarget. 2016 Jun 28;7(26):40690-40703. doi: 10.18632/oncotarget.9816. Oncotarget. 2016. PMID: 27276681 Free PMC article. - Reappraisal of glucocorticoids in castrate-resistant prostate cancer.
Sartor O, Parker CC, de Bono J. Sartor O, et al. Asian J Androl. 2014 Sep-Oct;16(5):666. doi: 10.4103/1008-682X.133314. Asian J Androl. 2014. PMID: 24994787 Free PMC article. - Current topics and perspectives relating to hormone therapy for prostate cancer.
Suzuki H, Kamiya N, Imamoto T, Kawamura K, Yano M, Takano M, Utsumi T, Naya Y, Ichikawa T. Suzuki H, et al. Int J Clin Oncol. 2008 Oct;13(5):401-10. doi: 10.1007/s10147-008-0830-y. Epub 2008 Oct 23. Int J Clin Oncol. 2008. PMID: 18946750 Review. - Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group.
Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA, Eisenberger MA, Higano C, Bubley GJ, Dreicer R, Petrylak D, Kantoff P, Basch E, Kelly WK, Figg WD, Small EJ, Beer TM, Wilding G, Martin A, Hussain M; Prostate Cancer Clinical Trials Working Group. Scher HI, et al. J Clin Oncol. 2008 Mar 1;26(7):1148-59. doi: 10.1200/JCO.2007.12.4487. J Clin Oncol. 2008. PMID: 18309951 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical